Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...
Credit: Takeda. Entyvio for SC use is expected to be available by the end of October 2023. The Food and Drug Administration (FDA) has approved the subcutaneous (SC) administration of Entyvio ® ...
REYKJAVIK, Iceland, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients ...
Entyvio is a brand-name prescription biologic drug. It contains the active ingredient vedolizumab. Biosimilars are generic versions of biologic medications, but only the brand-name version of this ...
The US Food and Drug Administration (FDA) has approved the subcutaneous (SC) administration of vedolizumab (Entyvio SC, Takeda) for maintenance therapy in adults with moderately to severely active ...
The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult participants, met all its primary endpoints The PK study ...
The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio ® in healthy adult participants, met all its primary endpoints REYKJAVIK, Iceland, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results